1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342–1356.

2. Yingchoncharoen T, Wu TC, Choi DJ, Ong TK, Liew HB, Cho MC. Economic burden of heart failure in Asian countries with different healthcare systems. Korean Circ J 2021;51:681–693.

3. Lee HH, Cho SMJ, Lee H, et al. Korea heart disease fact sheet 2020: analysis of nationwide data. Korean Circ J 2021;51:495–503.

4. Cho JY, Cho DH, Youn JC, et al. Korean Society of Heart Failure guidelines for the management of heart failure: definition and diagnosis. Korean Circ J 2023;53:195–216.

5. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart failure with recovered left ventricular ejection fraction: JACC Scientific Expert Panel. J Am Coll Cardiol 2020;76:719–734.

6. Authors/Task Force Members; McDonagh TA, et al.; Metra M. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131.

7. Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014;129:2380–2387.

8. Merlo M, Stolfo D, Anzini M, et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist? J Am Heart Assoc 2015;4:e001504.

9. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.

10. Sadek MHA, Aboul-Saud MI, El Missiri AM, Abdellatif YAM. Impact of angiotensin receptor-neprilysin inhibitor therapy on cardiac remodeling in patients with heart failure and reduced ejection fraction. J Cardiovasc Echogr 2025;35:23–31.

11. Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39:210–218.

12. Malgie J, Wilde MI, Brunner-La Rocca HP, et al. Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy. Eur Heart J 2025;46:2394–2405.

13. He Y, Ling Y, Guo W, et al. Prevalence and prognosis of HFimpEF developed from patients with heart failure with reduced ejection fraction: systematic review and meta-analysis. Front Cardiovasc Med 2021;8:757596.

14. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016;1:510–518.

15. Wang K, Youngson E, Bakal JA, Thomas J, McAlister FA, Oudit GY. Cardiac reverse remodelling and health status in patients with chronic heart failure. ESC Heart Fail 2021;8:3106–3118.

16. Nadruz W Jr, West E, Santos M, et al. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail 2016;9:e002826.

17. Lupón J, Díez-López C, de Antonio M, et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail 2017;19:1615–1623.

18. DeVore AD, Hellkamp AS, Thomas L, et al. The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. Eur J Heart Fail 2022;24:762–770.

19. Savarese G, Vedin O, D’Amario D, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail 2019;7:306–317.

20. Li Q, Qiao Y, Tang J, et al. Frequency, predictors, and prognosis of heart failure with improved left ventricular ejection fraction: a single-centre retrospective observational cohort study. ESC Heart Fail 2021;8:2755–2764.

21. Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J 2019;40:2110–2117.

22. Park CS, Park JJ, Mebazaa A, et al. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc 2019;8:e011077.

23. Park SY, Kong MG, Moon I, et al. Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction. Korean J Intern Med 2023;38:692–703.

24. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 2019;8:e012272.

25. Kim H, Oh J, Lee S, et al. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Sci Rep 2021;11:16335.

26. Januzzi JL, Butler J, Fombu E, et al. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). Am Heart J 2018;199:130–136.

27. Cunningham JW, Claggett BL, O’Meara E, et al. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol 2020;76:503–514.

28. Lee YH, Chiou WR, Hsu CY, et al. Different left ventricular re modelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment. Eur Heart J Cardiovasc Pharmacother 2022;8:118–129.

29. Liu Y, Zhong C, Si J, Chen S, Kang L, Xu B. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats. J Hypertens 2022;40:1822–1830.